Agents               Date         Indication                                                                       Age
approved
>65  (%)    >75 (%)
Ixabepilone [22]     10/2007      Combination   with capecitabine in metastatic or locally advanced           10       <1
breast cancer resistant to treatment with an anthracycline and a
taxane
10/2007      Monotherapy   in metastatic or locally advanced breast cancer resistant     13       3
to anthracyclines, taxanes, and capecitabine
Eribulin [23]        11/2010      Third-line treatment metastatic breast cancer                               15       2
Everolimus  [21]     7/2012       Advanced   hormone  receptor-positive, HER2-negative  breast cancer in      40       15
combination  with exemestane,  after failure of treatment with
letrozole or anastrozole
Ado-trastuzumab      2/2013       HER2-positive   breast cancer following treatment with trastuzumab          13       2
emtansine  [24]                    and a taxane
Pertuzumab  [25]     6/2012       Combination   with trastuzumab  and docetaxel in HER2-positive              15       1
metastatic breast cancer who have not received prior anti-HER2
therapy
Lapatinib [26, 27]   1/2010       Combination   with capecitabine in metastatic HER2-positive breast          17       1
cancer
Combination   with letrozole in metastatic HER2-positive breast cancer      44       12
